Cimerli Injection, Solution
NDC Package 70114-441-01

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. NDC HCPCS Crosswalk
    3. Frequently Asked Questions

Package Information

Cimerli (ranibizumab-eqrn) injection is a medication used to treat certain serious eye conditions (such as age-related macular degeneration, macular edema, diabetic retinopathy). This formulation utilizes a injection, solution delivery system. Marketed by Coherus Biosciences Inc, this product is identified by NDC 70114-441 and is authorized under FDA application BLA761165.

Identification & Billing

NDC Package Code
70114-441-01
Package Description
1 VIAL, SINGLE-DOSE in 1 CARTON / .05 mL in 1 VIAL, SINGLE-DOSE
Product Code
70114-441
11-Digit Billing Format
70114044101
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Cimerli
Non-Proprietary Name
Ranibizumab-eqrn
Substance Name
Ranibizumab
Dosage Form
Injection, Solution - A liquid preparation containing one or more drug substances dissolved in a suitable solvent or mixture of mutually miscible solvents that is suitable for injection.
Administration Route
Intravitreal - Administration within the vitreous body of the eye.
Active Ingredient(s)
RANIBIZUMAB .5 mg/.05mL
Pharmacologic Class
Usage Information
This medication is used to treat certain serious eye conditions (such as age-related macular degeneration, macular edema, diabetic retinopathy). It is used to help prevent decreased vision and blindness. Ranibizumab works by slowing the growth of abnormal new blood vessels in the eye and decreasing leakage from these blood vessels.

Regulatory & Marketing

Labeler Name
Coherus Biosciences Inc
Product Type
Human Prescription Drug
FDA Application #
BLA761165
Marketing Category
BLA - A product marketed under an approved Biologic License Application.
Start Marketing Date
10-03-2022
End Marketing Date
01-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Billing & HCPCS Mapping

To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.

Q5128
Source: ASP
Inj, cimerli, 0.1 mg
HCPCS Dosage 0.1 MG
Units / Pkg 5

Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 70114-441-01 identifies a specific commercial package of 1 vial, single-dose in 1 carton / .05 ml in 1 vial, single-dose of Cimerli, a human prescription drug labeled by Coherus Biosciences Inc. This injection, solution is formulated for intravitreal use and contains ranibizumab as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Coherus Biosciences Inc on October 03, 2022.

What are the primary indications for this medication?

This medication is used to treat certain serious eye conditions (such as age-related macular degeneration, macular edema, diabetic retinopathy). It is used to help prevent decreased vision and blindness. Ranibizumab works by slowing the growth of abnormal new blood vessels in the eye and decreasing leakage from these blood vessels.

How is this Coherus Biosciences Inc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 70114044101. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
70114-441-01
11-Digit CMS (5-4-2)
70114-0441-01

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.